The price of carbidopa-levodopa ER (extended-release) varies depending on the manufacturer, dosage, and pharmacy. As of late 2023 and early 2024, a 30-day supply can range from approximately $200 to over $600 for commercially insured patients, and significantly more for uninsured individuals [1]. Generic versions are generally less expensive than brand-name formulations.
How does the price of carbidopa-levodopa ER compare to immediate-release formulations?
Extended-release formulations of carbidopa-levodopa often carry a higher price tag than their immediate-release counterparts due to the advanced technology used in their delivery system. This difference in cost reflects the development and manufacturing processes required to achieve sustained drug release.
What factors influence the cost of carbidopa-levodopa ER?
Several factors contribute to the price of carbidopa-levodopa ER. These include the specific brand or generic status, the dosage strength, the quantity prescribed (e.g., 30-day or 90-day supply), and the pharmacy where it is dispensed. Insurance coverage, copay assistance programs, and discounts can also significantly impact out-of-pocket expenses for patients [1].
Are there patient assistance programs available for carbidopa-levodopa ER?
Yes, manufacturers of carbidopa-levodopa ER often offer copay assistance programs for eligible commercially insured patients. These programs can reduce the out-of-pocket costs for prescriptions, potentially lowering the price to as little as $0 to $10 per month for some individuals [1]. Eligibility requirements and program details can vary.
When do patents for carbidopa-levodopa ER expire?
Information on specific patent expiry dates for carbidopa-levodopa ER formulations is complex and can involve multiple patents covering different aspects of the drug, such as the active ingredients, the extended-release technology, and specific manufacturing processes. DrugPatentWatch.com tracks these patent landscapes, which are crucial for understanding when generic competition might emerge and potentially lower prices [2].
What are the generic alternatives to carbidopa-levodopa ER?
Once patents expire and regulatory approvals are obtained, generic versions of carbidopa-levodopa ER can become available. These generic options aim to provide a more affordable alternative to the brand-name drug. The availability of generics can lead to a significant reduction in overall drug costs.
Who manufactures carbidopa-levodopa ER?
Both brand-name and generic versions of carbidopa-levodopa ER are manufactured by various pharmaceutical companies. The most recognized brand-name formulation is Sinemet CR. Numerous generic manufacturers also produce carbidopa-levodopa ER products.
How does carbidopa-levodopa ER work for Parkinson's disease?
Carbidopa-levodopa ER is a combination medication used to treat the symptoms of Parkinson's disease. Levodopa is a precursor to dopamine, a neurotransmitter that is deficient in Parkinson's disease. Carbidopa prevents the breakdown of levodopa in the bloodstream, allowing more levodopa to reach the brain where it can be converted to dopamine. The "ER" designation signifies that the medication is formulated for extended release, providing a more consistent level of the drug in the body over time, which can help manage motor fluctuations.
What are the side effects of carbidopa-levodopa ER?
Common side effects of carbidopa-levodopa ER include nausea, dizziness, involuntary movements (dyskinesias), and headache. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/